1. Home
  2. GRCL

GRCL

Gracell Biotechnologies Inc.

Logo Gracell Biotechnologies Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

0

Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR.

Founded: 2017 Country:
China
China
Employees: N/A City: N/A
Market Cap: 989.9M IPO Year: 2021
Target Price: $11.88 AVG Volume (30 days): 1.4M
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.24 EPS Growth: N/A
52 Week Low/High: $1.40 - $10.44 Next Earning Date: 03-11-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: